News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
MethylGene Announces Two Oral Presentations Highlighting Its Lead HDAC Inhibitor MCGD0103 At The American Society of Clinical Oncology Annual Meeting
May 25, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
MethylGene Inc. (TSX: MYG) will be presenting three abstracts, two of which are oral presentations, at the American Society of Clinical Oncology (ASCO) 2006 Annual Meeting held in Atlanta from June 2 to 6, 2006.
Twitter
LinkedIn
Facebook
Email
Print